These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2752133)

  • 21. Predictive model for prognosis in advanced diffuse histiocytic lymphoma.
    Danieu L; Wong G; Koziner B; Clarkson B
    Cancer Res; 1986 Oct; 46(10):5372-9. PubMed ID: 3530438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic factors in low-grade lymphoma].
    Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
    Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prognostic factors, late relapse and outcome of patients with aggressive malignant lymphoma: long term results of LNH-80 protocol].
    Dumontet C; Bastion Y; Felman P; Ffrench M; Blanc M; Peaud PY; Bryon PA; Coiffier B
    Bull Cancer; 1992; 79(10):979-89. PubMed ID: 1284041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 25. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma.
    Binn M; Ruskoné-Fourmestraux A; Lepage E; Haioun C; Delmer A; Aegerter P; Lavergne A; Guettier C; Delchier JC
    Ann Oncol; 2003 Dec; 14(12):1751-7. PubMed ID: 14630680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
    Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
    Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell lymphomas: immunologic, histologic, clinical, and therapeutic analysis of 63 cases.
    Coiffier B; Berger F; Bryon PA; Magaud JP
    J Clin Oncol; 1988 Oct; 6(10):1584-9. PubMed ID: 3262720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80).
    Coiffier B; Bryon PA; Berger F; Archimbaud E; Ffrench M; Extra JM; Guyotat D; Fiere D; Gentilhomme O; Magaud JP
    J Clin Oncol; 1986 Feb; 4(2):147-53. PubMed ID: 2418166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
    Heinz R; Hanak H; Stacher A
    Klin Wochenschr; 1985 Jul; 63(14):619-26. PubMed ID: 3839867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
    Ferreri AJ; Blay JY; Reni M; Pasini F; Spina M; Ambrosetti A; Calderoni A; Rossi A; Vavassori V; Conconi A; Devizzi L; Berger F; Ponzoni M; Borisch B; Tinguely M; Cerati M; Milani M; Orvieto E; Sanchez J; Chevreau C; Dell'Oro S; Zucca E; Cavalli F
    J Clin Oncol; 2003 Jan; 21(2):266-72. PubMed ID: 12525518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma.
    Mok TS; Steinberg J; Chan AT; Yeo WM; Hui P; Leung TW; Johnson P
    Cancer; 1998 Jun; 82(12):2439-48. PubMed ID: 9635538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.
    Swan F; Velasquez WS; Tucker S; Redman JR; Rodriguez MA; McLaughlin P; Hagemeister FB; Cabanillas F
    J Clin Oncol; 1989 Oct; 7(10):1518-27. PubMed ID: 2674337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.
    López-Guillermo A; Cid J; Salar A; López A; Montalbán C; Castrillo JM; González M; Ribera JM; Brunet S; García-Conde J; Fernández de Sevilla A; Bosch F; Montserrat E
    Ann Oncol; 1998 Aug; 9(8):849-55. PubMed ID: 9789607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.
    Albain KS; Crowley JJ; LeBlanc M; Livingston RB
    J Clin Oncol; 1990 Sep; 8(9):1563-74. PubMed ID: 2167954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of patients with lymphomas of the uterus or cervix with combination chemotherapy and radiation therapy.
    Stroh EL; Besa PC; Cox JD; Fuller LM; Cabanillas FF
    Cancer; 1995 May; 75(9):2392-9. PubMed ID: 7712450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
    Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.